Using platelet-rich plasma with topical retinoids to treat acne vulgaris
Platelet-rich Plasma With Topical Retinoids Versus Topical Retinoids Alone in Acne Vulgaris: Randomized Clinical Trial
This study is testing if using platelet-rich plasma along with topical retinoids can help young people with acne clear their skin better than just using retinoids alone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 12 Years to 35 Years |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Locations | 1 site (Assiut) |
| Trial ID | NCT06281782 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of combining platelet-rich plasma (PRP) with topical retinoids in treating acne vulgaris, a common skin condition affecting adolescents and young adults. PRP is derived from the patient's own blood and contains growth factors that may enhance skin healing and regeneration. Participants aged 12 to 35 with facial acne vulgaris will be enrolled, while those with certain health conditions or unrealistic expectations will be excluded. The study aims to compare the outcomes of the combined treatment versus topical retinoids alone.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 12 to 35 with facial acne vulgaris.
Not a fit: Patients who may not benefit include those with chronic diseases, coagulation disorders, or unrealistic expectations regarding treatment outcomes.
Why it matters
Potential benefit: If successful, this approach could provide a more effective treatment option for patients suffering from acne vulgaris.
How similar studies have performed: While the use of PRP in dermatology is gaining attention, this specific combination with topical retinoids has not been extensively tested, making it a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with facial acne vulgaris * Age from 12 to 35 years old Exclusion Criteria: * Pregnant or lactating women. * patients with history of coagulation disorders. * chronic diseases (chronic renal failure, hepatic insufficiency, cardiovascular disorders, uncontrolled diabetes mellitus, thyroid disorders, anemia, autoimmune diseases). * patients with unrealistic expectations. * Patients received any systemic treatment in the last 6 months.
Where this trial is running
Assiut
- Faculty of Medicine — Assiut, Egypt (Recruiting)
Study contacts
- Study coordinator: Howida Omar Twisy
- Email: d.howida@aun.edu.eg
- Phone: +201029512930
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.